GleamWall
中文EN

ACUT Accustem Sciences Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1850767 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-7.2%
TTM EPS YoY8.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-102.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets356.4%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-27.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$281,014$138,324
SG&A expense$1.48M$1.37M
Operating income-$1.76M-$1.51M
Pretax income-$1.76M-$1.51M
Net income-$1.76M-$1.51M
EBITDA-$1.76M-$1.50M
EPS (basic)-0.12-0.13
EPS (diluted)-0.12-0.13
Weighted avg. shares (diluted)15.23M11.44M
Balance sheet
Cash & equivalents$13,929$5,046
Current assets$49,446$50,433
PP&E, net—$418
Total assets$1.55M$50,851
Current liabilities$4.95M$3.36M
Total liabilities$4.95M$3.36M
Shareholders' equity-$3.40M-$3.31M
Shares outstanding16.07M12.10M
Cash flow statement
Operating cash flow-$850,389-$664,066
Financing cash flow$859,271$647,632
Depreciation & amortization$418$3,630
Stock-based compensation$88,695$69,718

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.